-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 25, Sky announced that its subsidiary, Nord Pharmaceuticals, had received a Drug Registration Certificate on the Ebeshatan tablet approved by NMPA on January 23, 2021.
is used to treat primary hypertension and type 2 diabetic nephropathy, which combines high blood pressure.
treatment for primary hypertension and type 2 diabetic nephropathy, which combines hypertension, was first developed and marketed by Sanofi Pharmaceuticals of France under the name Aprovel.
According to the website of the Drug Review Center of the State Drug Administration, as of the date of the announcement, the specification preparation, in addition to the original pharmaceutical companies and Nord Pharmaceuticals, Hunan Jiuyuan Pharmaceutical Co., Ltd. and other 3 enterprises approved the listing after a consistent evaluation.
Drug Company's Ebershatan tablet was accepted by the State Drug Administration in March 2019 and currently has a cumulative research and development expenditure of approximately 8.3 million yuan.
